Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry-Reference-Cited by-同舟云学术

Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry

Published:2019-04 Issue:4 Volume:29 Page:530-539
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Hurst Zachary¹,Liyanarachchi Sandya²,He Huiling²,Brock Pamela³,Sipos Jennifer⁴,Nabhan Fadi⁴,Kebebew Electron⁵,Green Patience⁵,Cote Gilbert J.⁶,Sherman Steven⁶,Walker Christopher J.²,Chang Yi Seok¹,Xue Shuai¹,Hollingsworth Brynn¹,Li Wei²,Genutis Luke⁷,Menq Eric¹,de la Chapelle Albert²,Jhiang Sissy M.¹

Affiliation:

1. Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio.

2. Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.

3. Department of Human Genetics, Ohio State University College of Medicine, Columbus, Ohio.

4. Department of Endocrine, Diabetes, and Metabolism, Ohio State University College of Medicine, Columbus, Ohio.

5. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

6. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.

7. Department of Molecular Genetics, The Ohio State University, Columbus, Ohio.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2018.0687

Reference52 articles.

1. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution

2. Differentiated Thyroid Carcinoma

3. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

4. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers

5. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients;BMC Medicine;2024-07-18

2. Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis;Frontiers in Endocrinology;2024-05-15

3. Presumed Pathogenic Germ Line and Somatic Variants in African American Thyroid Cancer;Thyroid®;2024-01-18

4. Role of ST6GAL1 in Thyroid Cancers: Insights from Tissue Analysis and Genomic Datasets;International Journal of Molecular Sciences;2023-11-15

5. Risk Factors, Prognostic Indicators, and a Prognostic Nomogram for Distant Metastasis in Thyroid Cancer Patients without Lymph Node Metastasis;2023-10-18